Eli Lilly Initiates Phase 3 Trial of Lepodisiran, a Novel Lp(a)-Targeting siRNA Therapy

2024On March 4, Eli Lilly registered the Lpa siRNA therapy on the Clinicaltrials.gov website.LepodisiranPhase III clinical trials.

This Phase III clinical trial plans to enroll 12,500 patients with elevated Lp(a).AtherosclerosisOr patients at risk of cardiovascular events, expected to be completed in March 2029.

Lepodisiran was initially developed by Dicerna. In 2018, Eli Lilly and Company entered into a strategic collaboration with Dicerna to develop multiple siRNA therapies, with Lepodisiran being the second pipeline candidate from their partnership. Dicerna was acquired by Novo Nordisk for $3.3 billion in 2021.

At the end of 2023, the Phase I clinical data of Lepodisiran was published inJAMAThe journal showed that the effect of a single injection of Lepodisiran could last for a year.

AboutLepodisiran

Lepodisiran is an N-acetylgalactosamine-conjugated LPA-specific siRNA that reduces liver LPA mRNA levels to interfere with Apo(a) production, thereby lowering circulating Lp(a) levels.

About Eli Lilly and Company

Eli Lilly and Company is a globally leading pharmaceutical company engaged in the research, development, manufacturing, and marketing of medicines, committed to improving human health through innovation. Eli Lilly and Company was founded over a century ago by Colonel Eli Lilly in Indianapolis, Indiana, in 1876, with the founder dedicated to producing high-quality medicines to meet genuine medical needs.